Highlights

  • Tetratherix completed a ten-week preclinical study of TegenEOS as a carrier for platelet-rich plasma in tendon repair.
  • TegenEOS combined with PRP produced the most organised and aligned repair among the groups examined.
  • No foreign body reaction was observed in any TegenEOS sample at either time point.
  • The company plans an equine study and a dedicated PRP development pathway.

Tetratherix Limited (ASX:TTX) has announced the completion of a ten-week preclinical validation study assessing TegenEOS as a carrier for platelet-rich plasma (PRP) in tendon repair. The study explores a new orthopaedic application for TegenEOS, the company's bone graft carrier built on its Tetramatrix™ platform, and addresses a known challenge in delivering PRP to injury sites.

Addressing the PRP Delivery Challenge

Tendon and ligament injuries affect more than 30 million people worldwide each year. PRP is commonly used in orthopaedics and sports medicine, but it tends to disperse from the injury site within hours, before healing begins. TegenEOS is designed to be mixed with PRP, injected through a fine needle and set into a gel at body temperature, holding the PRP in place.

Founder and Chief Technology Officer Dr Ali Fathi said, "PRP has never had a biology problem. It has a delivery problem." He noted that the only difference between the study groups was the matrix holding the PRP in place.

Laboratory and Preclinical Results

In laboratory testing, TegenEOS mixed evenly with PRP, remained injectable through a fine needle, set at body temperature and released PRP proteins over a longer period than PRP alone. Key healing signals, including VEGF and HIF-1α, remained active.

In a patellar tendon defect model, four groups were compared: untreated, TegenEOS alone, PRP alone, and TegenEOS combined with PRP. Untreated defects did not heal on their own, and PRP alone produced inflamed, scar-like tissue. The TegenEOS and PRP group showed organised new blood vessels and reduced inflammation at six weeks, and by ten weeks it had the narrowest and most regularly aligned repair of the groups examined. No foreign body reaction was observed in any TegenEOS sample, and body and organ weights were comparable across groups.

Market Context and Next Steps

The global PRP market was estimated at more than US$700 million in 2026, with orthopaedics and sports medicine as its largest application. Tetratherix noted that TegenEOS requires no additional equipment, activators or additives and can be administered in outpatient clinics. The company intends to commercialise through partnerships, providing proof-of-concept and pilot data while partners handle regulatory approval, reimbursement and market planning.

Next steps include preparing an equine study to confirm the results in a larger animal model and developing a dedicated PRP development plan. Tetratherix will continue progressing TegenEOS toward US FDA 510(k) clearance as a bone graft carrier, while defining a separate regulatory pathway for PRP delivery as a different intended use.

Key Takeaways

  • The study suggests TegenEOS can help retain PRP at the injury site, addressing a key delivery limitation.
  • TegenEOS combined with PRP produced more organised tendon repair than PRP alone in the preclinical model.
  • No foreign body reaction was observed, supporting the safety profile seen in the study.
  • A larger animal study and a separate regulatory pathway for PRP delivery are the next steps.